Text Size

Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gary Kinasewitz, University of Oklahoma
ClinicalTrials.gov Identifier:
NCT00929565
First received: June 24, 2009
Last updated: April 5, 2012
Last verified: April 2012
History of Changes
  Purpose

Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway.

The investigators plan to measure these factors prior to and after bronchoscopy.


Condition
Hemoptysis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.

Resource links provided by NLM:

MedlinePlus related topics: Cancer
Drug Information available for: Urokinase
U.S. FDA Resources

Further study details as provided by University of Oklahoma:

Secondary Outcome Measures:
  • Volume of blood loss during the procedure [ Time Frame: 1 day ] [ Designated as safety issue: No ]

Enrollment: 10
Study Start Date: June 2009
Study Completion Date: October 2011
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Lung cancer
Comparison between individuals with and without pulmonary malignancy

Detailed Description:

This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients from the VAMC in Oklahoma city

Criteria

Inclusion Criteria:

  • Any patient scheduled to undergo bronchoscopy

Exclusion Criteria:

  • Patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000
  • Patients not scheduled to undergo bronchoalveolar lavage (BAL)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00929565

Locations
United States, Oklahoma
VA Medical Center
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
University of Oklahoma
Investigators
Principal Investigator: Jijo John, MD University of Oklahoma
  More Information

No publications provided

Responsible Party: Gary Kinasewitz, Principal Investigator, University of Oklahoma
ClinicalTrials.gov Identifier: NCT00929565     History of Changes
Other Study ID Numbers: 14455
Study First Received: June 24, 2009
Last Updated: April 5, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Oklahoma:
hemoptysis

Additional relevant MeSH terms:
Hemoptysis
Lung Diseases
Respiratory Tract Diseases
Hemorrhage
Pathologic Processes
Signs and Symptoms, Respiratory
Signs and Symptoms
Plasminogen
 Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses
Hematologic Agents

ClinicalTrials.gov processed this record on May 22, 2013